Across TCGA pan-cancer cohorts, ERV3-1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ERV3-1 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ERV3-1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ERV3-1 expression acts as an unfavorable survival marker.
HNSC, LUAD, and BLCA are the cancer types where ERV3-1 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.